Get started
Author

Scott Kopetz

Observed names: Kopetz, Scott, S. Kopetz, S.W. Kopetz, Scott W Kopetz
ORCID: 0000-0001-9647-3416
Observed ORCID: 0000-0001-9647-3416
OpenAlex ID: A5044880243
Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases
2022 · Yujiro Nishioka, Yun Shin Chun, et al. · Journal of the American College of Surgeons · 33
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
2025 · Van K. Morris, Christine M. Parseghian, et al. · Cancer Cell · 28
Fructose and glucose from sugary drinks enhance colorectal cancer metastasis via SORD
2025 · Tianshi Feng, Qin Luo, et al. · Nature Metabolism · 18
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
2026 · Michael Cecchini, Sae-Won Han, et al. · Clinical Cancer Research · 8
PDF
BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
2025 · Scott Kopetz, Takayuki Yoshino, et al. · Journal of Clinical Oncology · 5
PDF
Adagrasib (Ada) + cetuximab (Cetux) for KRAS G12C -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.
2025 · Rona Yaeger, Nataliya V. Uboha, et al. · Journal of Clinical Oncology · 5
PDF
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program
2026 · Salvador Alonso, Kanwal Raghav, et al. · Cancer Cell · 3
Delineating the copy-number substructure of metastatic tumors with CopyKit
2026 · Junke Wang, Darlan Conterno Minussi, et al. · Molecular Cell · 3
Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
2025 · Giulia Maddalena, Ymke van der Pol, et al. · JNCI Journal of the National Cancer Institute · 2
939P Phase I, dose-escalation study evaluating safety & efficacy of trastuzumab deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, ceralasertib) in advanced solid tumors with HER2 expression (DASH)
2025 · K. Raghav, Y. Yuan, et al. · Annals of Oncology · 2
PDF
Chromosome 20q gene signature associated with colorectal cancer progression
2025 · Jennifer Jones, Apurva Hegde, et al. · Oncology Reports · 2
PDF
Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF V600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies.
2025 · Kelsey Pan, Yunyu Baig, et al. · Journal of Clinical Oncology · 2
PDF
Dual checkpoint blockade for microsatellite instability-high colorectal cancer
2025 · S Daniel Haldar, Scott Kopetz · The Lancet · 2
Patterns of progression and survival in patients with mismatch repair deficient/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy
2026 · Michael LaPelusa, Preksha Shah, et al. · The Oncologist · 1
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
2026 · Scott Kopetz, Josep Tabernero, et al. · Journal of Clinical Oncology · 1
The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy
2026 · Andrea H. Bild, Michelle C. Sangar, et al. · Cancer Cell · 1
Functional modules predict genetic interactions, revealing evolutionary conservation and rewiring
2025 · Chenchu Lin, Veronica Gheorghe, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
569 A phase 1/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors
2025 · Rodabe Amaria, Khaled Sanber, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
2025 · E. Elez Fernandez, E. Garralda, et al. · Annals of Oncology · 1
PDF
Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).
2025 · Guglielmo Vetere, Ryan Sun, et al. · Journal of Clinical Oncology · 1
Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study.
2025 · Emerik Osterlund, Giulia Maddalena, et al. · Journal of Clinical Oncology · 1
A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.
2025 · Rodabe Navroze Amaria, Scott Kopetz, et al. · Journal of Clinical Oncology · 1
PDF
Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models
2026 · Jose Maldonado, Thomas Wong, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients
2026 · Guglielmo Vetere, Emerik Osterlund, et al. · Journal for ImmunoTherapy of Cancer
Response to Zhang
2026 · Giulia Maddalena, Scott Kopetz, et al. · JNCI Journal of the National Cancer Institute
Works count: 58
Citation count: 122
H-index: 5
I10-index: 3
Year
Topic
Type